跳转至内容
Merck
CN
  • N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy.

N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy.

Annals of neurology (2002-11-26)
Orly Elpeleg, Avraham Shaag, Efrat Ben-Shalom, Tal Schmid, Claude Bachmann
摘要

Carbamylphosphate synthase is the first enzymatic reaction of the urea cycle. Its activator, N-acetylglutamate, is synthesized from acetyl-CoA and glutamate in a reaction catalyzed by N-acetylglutamate synthase (NAGS). We have identified the putative human NAGS gene and report the first mutation in this gene in a family with carbamylglutamate responsive hyperammonemia and normal activity of the urea cycle enzymes. Mutation analysis has a higher diagnostic specificity than the enzymatic assay in NAGS deficiency. A therapeutic trial with carbamylglutamate is recommended whenever hyperammonemia without an organic aciduria, increased orotate excretion, or diagnostic amino acidemia/uria is detected.